Medtronic receives fda approval for latest generation drug-eluting coronary stent system

The onyx frontier™ drug-eluting stent offers an innovative delivery system and builds upon the acute performance and clinical data from the resolute onyx™ drug-eluting stent dublin , may 13, 2022 /prnewswire/ -- medtronic plc (nyse:mdt), a global leader in healthcare technology, today announced it received u.s. food and drug administration (fda) approval for the onyx frontier™ drug-eluting stent (des). as the latest evolution in the resolute des family, onyx frontier des leverages the same best-in-class stent platform as resolute onyx™ des, with an enhanced delivery system1 designed to improve deliverability and increase acute performance2 in even the most challenging of cases.1 the onyx frontier des is used for the treatment of patients with coronary artery disease (cad), which is caused by plaque buildup on the inside of the coronary arteries.
MDT Ratings Summary
MDT Quant Ranking